DUBLIN, IRELAND — Neuromod, the medical device company behind the Lenire tinnitus treatment device, has announced the launch of Tinnitus Masterclass, an online course designed to provide hearing care professionals with clinical and commercial knowledge to establish effective and sustainable tinnitus care services.
Tinnitus Masterclass is an expert-led online program that integrates audiology, neurology, and psychology into short, focused modules. The curriculum covers tinnitus etiology, assessment, treatment options, and patient guidance.
To support the commercial viability of tinnitus services in clinical settings, the course also includes modules on the economics of tinnitus, defining service offerings, and marketing specialized tinnitus care.
Improving Access to Tinnitus Care
Tinnitus, often described as ringing in the ears, affects an estimated 15% of adults globally1. Despite this prevalence, nearly half of all tinnitus patients wait more than two months for specialist care, according to a 2024 Tinnitus UK report2.
Neuromod’s Director of Clinical Affairs and Tinnitus Masterclass coordinator, Dr. Jakob Kümmel, said the course is designed to expand access to tinnitus services:
“Neuromod created the Tinnitus Masterclass to empower hearing-care professionals with the knowledge, confidence, and tools to deliver truly patient-centered tinnitus care. Our goal is to raise the standard of tinnitus care globally — enabling clinicians to bridge science, evidence, and empathy while developing models of care that are both effective for patients and viable for their practices.”
A Curriculum Developed by Experts
Tinnitus Masterclass was developed by Neuromod in collaboration with leading tinnitus clinicians, researchers, and business professionals. Contributors include Dr. Jason Leyendecker, AuD, Academy of Doctors of Audiology Past President and Tinnitus & Hyperacusis Clinic owner; Dr. Melissa Wikoff, AuD, Peachtree Audiology owner; Dr. Emily E. McMahan, President of the Audiology Practice Standards Organization and Alaska Hearing & Tinnitus Center owner; Prof. Gail Whitelaw, Past President of the American Academy of Audiology and Director of the Speech-Language-Hearing Clinic at The Ohio State University; and Dr. Jennifer Gans, PhD, creator of Mindfulness-Based Tinnitus Stress Reduction.
The course combines insights from experienced tinnitus practitioners with Neuromod’s experience training hundreds of hearing healthcare professionals and conducting extensive tinnitus research. Neuromod has completed three large-scale clinical trials for Lenire — the first and only FDA-approved bimodal neuromodulation tinnitus treatment device. These studies demonstrated the device’s safety and effectiveness across more than 600 participants3,4,5.
Lenire’s real-world outcomes align closely with clinical trial findings6, supported by Neuromod’s structured clinician training and evidence-based approach. According to the company, practices providing specialized tinnitus care, including Lenire, have reported both patient success and business growth.
“Demand for tinnitus care from expert clinicians is significant. Building the knowledge and confidence of clinicians interested in helping tinnitus patients is critical to serving the global patient population,” said Dr. Ross O’Neill, PhD, Neuromod Founding CEO.
“Tinnitus Masterclass delivers this by combining expertise from some of the most experienced tinnitus clinicians practising today with Neuromod’s significant experience training audiology and ENT practices in clear, practical lessons.”
Enrollment Information
Hearing healthcare professionals who wish to introduce or expand tinnitus care services in their practice can register for Tinnitus Masterclass at neuromod.com/tinnitus-masterclass.
The course is accessible via web browser or mobile app on iOS or Android. Tinnitus Masterclass is currently available to European healthcare professionals in English, with additional languages and regional access in development.
About Neuromod
Founded in 2010, Neuromod Devices is a global medical technology company with offices in Ireland, Germany, and the United States. The company specializes in the design and development of neuromodulation technologies addressing the clinical needs of underserved patient populations.
The lead application of Neuromod’s technology is in tinnitus treatment. The company has conducted extensive clinical trials confirming the efficacy of its non-invasive neuromodulation platform in this condition. For more information, visit www.neuromod.com.
References
- Tinnitus UK, Struggle for Silence Report, 2024.
- Global Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis, JAMA (2022).
- Conlon, B. et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports 12, 10845 (2022).
- Conlon, B. et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine 12, eabb2830 (2020).
- Boedts, M. B. A., Khoo, G., et al. Combining sound with tongue stimulation clinically improves tinnitus symptoms in a controlled pivotal trial. Nature Communications (2024).
- McMahan, E., and Lim, H. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Commun Med (2025). https://doi.org/10.1038/s43856-025-00837-3.
Source: Neuromod
